Valuation: SCYNEXIS, Inc.

Market Cap 3.82Cr 3.35Cr 3.09Cr 2.89Cr 5.42Cr 360.65Cr 5.54Cr 37Cr 14Cr 178.24Cr 14Cr 14Cr 618.06Cr P/E 2026 *
-0.94x
P/E 2027 * -1.53x
Enterprise Value 3.82Cr 3.35Cr 3.09Cr 2.89Cr 5.42Cr 360.65Cr 5.54Cr 37Cr 14Cr 178.24Cr 14Cr 14Cr 618.06Cr EV / Sales 2026 *
33.1x
EV / Sales 2027 * 5.73x
Free-Float
98.15%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: SCYNEXIS, Inc.

1 day+1.05%
1 week-4.94%
Current month-31.74%
1 month-29.33%
3 months-42.54%
6 months-18.03%
Current year-23.90%
1 week 3.68
Extreme 3.68
4.02
1 month 3.68
Extreme 3.68
6.16
Current year 3.68
Extreme 3.68
9.12
1 year 3.68
Extreme 3.68
10.48
3 years 3.68
Extreme 3.68
30.96
5 years 3.68
Extreme 3.68
65.71
10 years 3.68
Extreme 3.68
440.8
Manager TitleAgeSince
Chief Executive Officer 61 01/01/2023
Director of Finance/CFO 65 24/10/2022
Chief Tech/Sci/R&D Officer - 01/10/2020
Director TitleAgeSince
Director/Board Member 73 01/12/2008
Chairman 67 04/06/2015
Director/Board Member 61 01/01/2023
Date Insider Type Main position Quantity % Market Cap.
01/04Buy

Chief Executive Officer

2,17,390 0.2736%
29/01Free

Chief Financial Officer

1,29,833 0.3094%
29/01Free

Chief Executive Officer

3,91,333 0.9325%
Change 5-day change 1-year change 3-year change Capi.($)
+1.05%-4.94%-34.66%-82.81% 3.78Cr
+7.13%+9.97%+51.94%+166.83% 1,00600Cr
+3.99%+11.50%+67.53%+55.63% 59TCr
+4.20%+17.03%+35.63%+87.74% 43TCr
+0.99%+4.85%+27.93%+22.82% 33TCr
+1.82%+8.19%+41.15%+26.80% 29TCr
+0.22%+6.75%+31.51%+42.02% 28TCr
+0.73%+8.53%-26.22%-40.85% 21TCr
+1.56%+6.14%+28.38%+59.45% 19TCr
+3.26%+3.33%+18.83%+67.03% 15TCr
Average +1.96%+7.02%+24.20%+40.47% 34.86TCr
Weighted average by Cap. +2.25%+9.14%+40.20%+79.87%

Financials

2026 *2027 *
Net sales 11.54L 10.12L 9L 9L 16.37L 11Cr 16.71L 1.12Cr 43.38L 5.38Cr 43.33L 42.39L 19Cr 66.77L 58.55L 53.97L 50.52L 94.74L 63Cr 96.71L 6.49Cr 2.51Cr 31Cr 2.51Cr 2.45Cr 107.95Cr
Net income -4.11Cr -3.6Cr -3.32Cr -3.11Cr -5.83Cr -387.46Cr -5.95Cr -40Cr -15Cr -191.49Cr -15Cr -15Cr -664Cr -2.87Cr -2.52Cr -2.32Cr -2.17Cr -4.08Cr -271.01Cr -4.16Cr -28Cr -11Cr -133.94Cr -11Cr -11Cr -464.45Cr
Net Debt - -
Logo SCYNEXIS, Inc.
SCYNEXIS, Inc. is a biotechnology company focused on developing therapies to address severe rare diseases. The Company's SCY-770 is being developed for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) and has been granted Orphan Drug designation. Its proprietary antifungal platform, fungerps, includes BREXAFEMME (ibrexafungerp tablets), which has been licensed to GSK, and SCY-247, which is in clinical stages of development. Its SCY-770 is a novel, highly selective, direct AMP-activated protein kinase (AMPK) activator for the treatment of ADPKD, a genetic cause of end-stage renal failure. Its SCY-770 is designed to address many of the underlying drivers of ADPKD by reducing cyst growth and disease progression. The United States Food and Drug Administration (FDA) has approved BREXAFEMME (ibrexafungerp tablets) for treatment of patients with vulvovaginal candidiasis (VVC) and for the reduction in the incidence of recurrent vulvovaginal candidiasis (rVVC).
Employees
18
Date Price Change Volume
26/26/26 $3.850 +1.05% 49,093
25/26/25 $3.810 -1.55% 47,373
24/26/24 $3.870 +1.31% 28,667
23/26/23 $3.820 +0.53% 76,803
22/26/22 $3.800 -6.17% 1,18,391
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
3.850USD
Average target price
33.55USD
Spread / Average Target
+771.34%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SCYX Stock